M.D. Anderson Cancer Center
To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.
Primary Objective: \- Rate of bone marrow undetectable Measurable Residual Disease (10-4 sensitivity; uMRD4) at end of Cycle 13. Secondary Objectives: * Blood uMRD6 rate at end of cycles 9, 13, 19, 25. * 2018 iwCLL response rates defined as complete response (CR), CR with incomplete count recovery (CRi), partial response (PR), overall response (OR), stable disease (SD), and progressive disease (PD) at cycle 13. * Progression-free (PFS) and overall survival (OS); time to blood uMRD6 relapse; safety and tolerability.
Eligibility Criteria: 1. Age 18 years or older. 2. Diagnosis of CLL/SLL per 2018 iwCLL criteria (See Appendix 1). 3. Participants with previously treated CLL requiring therapy based on 2018 iwCLL criteria. 4. The participant is able to take oral medications. 5. Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. 6. Prior or ongoing therapy with covalent BTKi is allowed, but not required. 7. Prior or ongoing therapy (at least for six months) with BCL2i is allowed, b…
Given PO 200mg daily
Given PO daily
Given IV 100mg day 1, 900 mg day 2, 100mg days 8, 15
Arctuva estimate
Verify or correct the compensation shown for this listing.